In an expert view, Maggie Chang, vice president, regulatory affairs, at China-based Hangzhou Tigermed Consulting, takes a look at what is now happening in China’s amended new drug approval system.
On September 5, China’s National Medical Products Administration (NMPA) announced the approval of the new drug application (NDA) for Soliris (eculizumab) Injection for the treatment of patients with PNH and aHUS in adults and children.
Both are rare diseases listed also by the Chinese government a few months ago. This product was developed by the USA’s Alexion Pharmaceuticals (Nasdaq: ALXN), while the CTA/NDA application in China was successfully handled by Tigermed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze